CL2020002050A1 - Nemolizumab en el tratamiento de dermatitis atópica con excoriación moderada a grave - Google Patents

Nemolizumab en el tratamiento de dermatitis atópica con excoriación moderada a grave

Info

Publication number
CL2020002050A1
CL2020002050A1 CL2020002050A CL2020002050A CL2020002050A1 CL 2020002050 A1 CL2020002050 A1 CL 2020002050A1 CL 2020002050 A CL2020002050 A CL 2020002050A CL 2020002050 A CL2020002050 A CL 2020002050A CL 2020002050 A1 CL2020002050 A1 CL 2020002050A1
Authority
CL
Chile
Prior art keywords
atopic dermatitis
treatment
nemolizumab
excoriation
moderate
Prior art date
Application number
CL2020002050A
Other languages
English (en)
Inventor
Nabil Kerrouche
Keiko Hirokawa
Ryosuke Mihara
Original Assignee
Nestle Skin Health Sa
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65729402&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2020002050(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestle Skin Health Sa, Chugai Pharmaceutical Co Ltd filed Critical Nestle Skin Health Sa
Publication of CL2020002050A1 publication Critical patent/CL2020002050A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En la presente memoria se revelan métodos para el tratamiento selectivo de la dermatitis atópica (AD) en un sujeto que tiene excoriaciones de la piel, composiciones farmacéuticas para su uso en el tratamiento de la dermatitis atópica en un sujeto que tiene excoriaciones de la piel, usos de nemolizumab o un equivalente en la fabricación de un medicamento para el tratamiento de la dermatitis atópica en un sujeto que tiene excoriaciones de la piel, y métodos para la identificación de un sujeto que tiene dermatitis atópica que es probable que responda al tratamiento con nemolizumab o un equivalente del mismo.
CL2020002050A 2018-02-09 2020-08-07 Nemolizumab en el tratamiento de dermatitis atópica con excoriación moderada a grave CL2020002050A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862628714P 2018-02-09 2018-02-09

Publications (1)

Publication Number Publication Date
CL2020002050A1 true CL2020002050A1 (es) 2020-12-11

Family

ID=65729402

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002050A CL2020002050A1 (es) 2018-02-09 2020-08-07 Nemolizumab en el tratamiento de dermatitis atópica con excoriación moderada a grave

Country Status (23)

Country Link
US (2) US12435147B2 (es)
EP (2) EP4644424A3 (es)
JP (3) JP7777921B2 (es)
CN (1) CN112040976A (es)
AU (2) AU2019219608B2 (es)
BR (1) BR112020016144A2 (es)
CA (1) CA3090062A1 (es)
CL (1) CL2020002050A1 (es)
DK (1) DK3749353T3 (es)
ES (1) ES3049513T3 (es)
FI (1) FI3749353T3 (es)
HR (1) HRP20251101T1 (es)
IL (1) IL276524A (es)
LT (1) LT3749353T (es)
MX (1) MX2020008193A (es)
PH (1) PH12020551185A1 (es)
PL (1) PL3749353T3 (es)
PT (1) PT3749353T (es)
RU (1) RU2758378C1 (es)
SG (1) SG11202007558YA (es)
SI (1) SI3749353T1 (es)
TW (2) TWI856006B (es)
WO (1) WO2019155427A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202535464A (zh) * 2023-11-02 2025-09-16 日商丸寶股份有限公司 醫藥組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
DK1188830T3 (da) 1999-06-02 2010-04-26 Chugai Pharmaceutical Co Ltd Nyt hæmopoietinreceptorprotein NR10
EP1858924A1 (en) * 2005-02-14 2007-11-28 ZymoGenetics, Inc. Methods of treating skin disorders using an il-31ra antagonist
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
CN105859889B (zh) * 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
FI3284480T3 (fi) * 2015-04-14 2025-09-11 Chugai Pharmaceutical Co Ltd IL-31-antagonistia vaikuttavana ainesosana sisältävä farmaseuttinen koostumus atooppisen ihottuman ehkäisemiseksi ja/tai hoitamiseksi
WO2017093857A1 (en) * 2015-11-30 2017-06-08 Anacor Pharmaceuticals, Inc. Topical pharmaceutical formulations for treating inflammatory-related conditions

Also Published As

Publication number Publication date
IL276524A (en) 2020-09-30
JP2023182632A (ja) 2023-12-26
EP4644424A3 (en) 2026-01-14
TW202448919A (zh) 2024-12-16
WO2019155427A1 (en) 2019-08-15
RU2758378C1 (ru) 2021-10-28
CA3090062A1 (en) 2019-08-15
TWI856006B (zh) 2024-09-21
EP3749353A1 (en) 2020-12-16
AU2019219608A1 (en) 2020-08-27
PH12020551185A1 (en) 2021-05-17
HRP20251101T1 (hr) 2025-11-21
JP7777921B2 (ja) 2025-12-01
US20200385476A1 (en) 2020-12-10
SI3749353T1 (sl) 2025-10-30
EP3749353B1 (en) 2025-07-30
TWI923998B (zh) 2026-05-01
JP2025176134A (ja) 2025-12-03
AU2019219608B2 (en) 2025-10-16
US12435147B2 (en) 2025-10-07
AU2026200182A1 (en) 2026-01-29
EP4644424A2 (en) 2025-11-05
MX2020008193A (es) 2020-11-24
LT3749353T (lt) 2025-09-25
TW201941800A (zh) 2019-11-01
JP2021512917A (ja) 2021-05-20
US20260008859A1 (en) 2026-01-08
SG11202007558YA (en) 2020-09-29
PL3749353T3 (pl) 2025-12-08
ES3049513T3 (en) 2025-12-17
DK3749353T3 (da) 2025-09-01
FI3749353T3 (fi) 2025-09-10
BR112020016144A2 (pt) 2020-12-15
PT3749353T (pt) 2025-10-14
CN112040976A (zh) 2020-12-04

Similar Documents

Publication Publication Date Title
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
ECSP22038978A (es) INHIBICIÓN DE INTEGRINA ALFA4ß7 HUMANA
BR112017028413A2 (pt) peptídeos antimicrobianos estabilizados
MX2017011269A (es) Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos.
MX2017015938A (es) Inhibidores de ezh2 para el tratar linfomas.
MX389847B (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
MX2021003110A (es) Agonistas del receptor x farnesoide y usos de los mismos.
PE20160949A1 (es) Cepa aislada de clonostachys rosea para uso como agente de control biologico
MX2017006113A (es) Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).
MX2018004177A (es) Terapia de combinacion para el tratamiento de cancer.
NI201600071A (es) Compuestos de inhibidor de autotaxina
BR112018001435A2 (pt) métodos para entrega linfática de agentes ativos
CL2019001329A1 (es) Composiciones farmacéuticas moduladoras del receptor 7 de 5-hidroxitritpina y métodos de uso.
CO2023013465A2 (es) Composiciones y métodos para inhibir cetohexoquinasa (khk)
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
MX379359B (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
MX2017015292A (es) Composicion para tratar lesiones cerebrales.
MX2021000542A (es) Apirasas solubilizadas, metodos y usos.
MX2020005235A (es) Celula humana transformada y uso de la misma.
BR112018067967A2 (pt) tratamento de pacientes com hipercolesterolemia familiar homozigótica por meio de terapia hipolipemiante
BR112017024908A2 (pt) usos terapêuticos da 4-cloroquinurenina
MX2018014135A (es) Tratamiento del dolor.
CL2020000221A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.